Bruce Greenberg
Interim Chief Financial Officer
Replay available
Aldeyra Therapeutics, Inc. (ALDX) Q2 2022 Earnings Call
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Q2 2022 earnings conference call, held 2022-08-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Tom Schrader
BTIG
Dr. Todd Brady
President and Chief Executive Officer
Not Provided
Not Provided
Yael Jen
Laidlaw and Company
Catherine Novak
Jones Research
Justin Kim
Oppenheimer & Co
Kelly Shi
Jefferies
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aldeyra Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.049 -- 00:00:04.192 Ladies and gentlemen, thank you for standing by and welcome to the Aldera Therapeutics 00:00:04.192 -- 00:00:07.994 second quarter 2022 financial results conference call. 00:00:07.994 -- 00:00:11.296 At this time, all participants are in a listen-only mode. 00:00:11.296 -- 00:00:15.299 After the speaker's presentation, there will be a question and answer session. 00:00:15.299 -- 00:00:19.541 I would now like to hand over the conference to the company's interim chief financial 00:00:19.541 -- 00:00:24.383 officer, Mr. Bruce Greenberg. Please go ahead, sir. 00:00:24.764 -- 00:00:27.615 Good morning, everyone. With me today is Dr. 00:00:27.615 -- 00:00:31.297 Todd Brady, our President and Chief Executive Officer. 00:00:31.297 -- 00:00:35.059 This morning, we issued a press release reporting our financial results for the quarter 00:00:35.059 -- 00:00:39.721 ended June 30th, 2022 in recent corporate highlights. 00:00:39.721 -- 00:00:44.484 A copy of the press release is available on the investor and media section of our website 00:00:44.484 -- 00:00:46.864 at www.aldera.com. 00:00:49.947 -- 00:00:54.490 Please note that this morning's conference call contains forward-looking statements regarding 00:00:54.490 -- 00:00:58.527 future events in the future performance of Eldera. 00:00:58.527 -- 00:01:02.569 Forward-looking statements include, but are not limited to, statements regarding submission 00:01:02.569 -- 00:01:07.852 of potential new drug applications, potential commercialization, the anticipated timing 00:01:07.852 -- 00:01:11.113 of results from our clinical trials, 00:01:11.113 -- 00:01:16.856 our projected cash runway, our possible or assumed future results of operations, 00:01:16.856 -- 00:01:21.377 expenses and financial posit...